Marte A M van Hylckama Vlieg, Kazem Nasserinejad, Chantal Visser, Wichor M Bramer, Aneel A Ashrani, Jean-Luc Bosson, Daniel J Crusan, Andrea D'Alessio, Meg E Fluharty, Valdis Ģībietis, Per-Olof Hansson, Nobuhiro Hara, Luis Jara-Palomares, Noémie Kraaijpoel, Isabelle Mahé, Andrea Marshall, Yutaka Ogino, Remedios Otero, Jorie Versmissen, Frederikus A Klok, Marieke J H A Kruip, Carin C D van der Rijt, Eric C T Geijteman
BACKGROUND: The optimal duration of anticoagulation in patients with active cancer and venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate anticoagulant therapy for 3-6 months and to continue anticoagulant therapy for as long as the cancer is active. However, an adequate systematic review on the rate of recurrent VTE after discontinuation of anticoagulant therapy has not been performed. METHODS: For this systemic review and meta-analysis, we searched Embase...
October 2023: EClinicalMedicine